China deaths reignite debate about using viruses to deliver CRISPR therapiesnews2026-09-02T14:00:43+00:00September 2nd, 2026|Endpoints News|
Typewriter raises $56M for jumping gene technology and in vivo CAR-T therapiesnews2026-09-02T11:00:57+00:00September 2nd, 2026|Endpoints News|
ARPA-H awards $125M for manufacturing custom RNA therapies on demandnews2026-09-01T18:32:08+00:00September 1st, 2026|Endpoints News|
Three takeaways from Trump’s latest drug pricing eventnews2026-09-01T18:16:50+00:00September 1st, 2026|Endpoints News|
Arsenal Biosciences cuts ‘majority’ of staff in move to in vivo CAR-Tnews2026-09-01T17:12:58+00:00September 1st, 2026|Endpoints News|
Lilly’s 2026 dealmaking spreads the wealth among biotech venture investorsnews2026-09-01T15:01:06+00:00September 1st, 2026|Endpoints News|
GSK to launch Phase 3 test of mRNA flu vaccine with newer formulationnews2026-09-01T14:40:34+00:00September 1st, 2026|Endpoints News|
Roche taps Simcere for trispecific T cell engager pact with $75M upfrontnews2026-09-01T14:40:27+00:00September 1st, 2026|Endpoints News|
Alumis’ TYK2 drug fails in lupus trial; CEO sees ‘clear path forward’news2026-09-01T14:24:39+00:00September 1st, 2026|Endpoints News|
